Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors
(2022) In RSC Advances 12(29). p.18973-18984- Abstract
Galectins are galactoside-binding proteins that play a role in various pathophysiological conditions, making them attractive targets in drug discovery. We have designed and synthesised a focused library of aromatic 3-triazolyl-1-thiogalactosides targeting their core site for binding of galactose and a subsite on its non-reducing side. Evaluation of their binding affinities for galectin-1, -3, and -8N identified acetamide-based compound 36 as a suitable compound for further affinity enhancement by adding groups at the reducing side of the galactose. Synthesis of its dichlorothiophenyl analogue 59 and the thiodigalactoside analogue 62 yielded promising pan-galectin inhibitors.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/48838ddf-693a-4235-93f2-91c7f382ebec
- author
- van Klaveren, Sjors LU ; Dernovšek, Jaka ; Jakopin, Žiga ; Anderluh, Marko ; Leffler, Hakon LU ; Nilsson, Ulf J. LU and Tomašič, Tihomir
- organization
- publishing date
- 2022-06-30
- type
- Contribution to journal
- publication status
- published
- subject
- in
- RSC Advances
- volume
- 12
- issue
- 29
- pages
- 12 pages
- publisher
- Royal Society of Chemistry
- external identifiers
-
- pmid:35873334
- scopus:85134351063
- ISSN
- 2046-2069
- DOI
- 10.1039/d2ra03163a
- language
- English
- LU publication?
- yes
- id
- 48838ddf-693a-4235-93f2-91c7f382ebec
- date added to LUP
- 2022-09-22 15:46:22
- date last changed
- 2024-11-15 12:35:24
@article{48838ddf-693a-4235-93f2-91c7f382ebec, abstract = {{<p>Galectins are galactoside-binding proteins that play a role in various pathophysiological conditions, making them attractive targets in drug discovery. We have designed and synthesised a focused library of aromatic 3-triazolyl-1-thiogalactosides targeting their core site for binding of galactose and a subsite on its non-reducing side. Evaluation of their binding affinities for galectin-1, -3, and -8N identified acetamide-based compound 36 as a suitable compound for further affinity enhancement by adding groups at the reducing side of the galactose. Synthesis of its dichlorothiophenyl analogue 59 and the thiodigalactoside analogue 62 yielded promising pan-galectin inhibitors.</p>}}, author = {{van Klaveren, Sjors and Dernovšek, Jaka and Jakopin, Žiga and Anderluh, Marko and Leffler, Hakon and Nilsson, Ulf J. and Tomašič, Tihomir}}, issn = {{2046-2069}}, language = {{eng}}, month = {{06}}, number = {{29}}, pages = {{18973--18984}}, publisher = {{Royal Society of Chemistry}}, series = {{RSC Advances}}, title = {{Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors}}, url = {{http://dx.doi.org/10.1039/d2ra03163a}}, doi = {{10.1039/d2ra03163a}}, volume = {{12}}, year = {{2022}}, }